STAGE IVA OVARIAN CANCER AJCC V8
Clinical trials for STAGE IVA OVARIAN CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA OVARIAN CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVA OVARIAN CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Keytruda takes on genetic weak spots in advanced tumors
Disease control OngoingThis phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…
Matched conditions: STAGE IVA OVARIAN CANCER AJCC V8
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early trial is testing whether the drug olaparib can shrink tumors in people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they have surgery. Fifteen participants will receive olaparib for two cycles, then undergo standard chemotherapy…
Matched conditions: STAGE IVA OVARIAN CANCER AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Blood test may help cancer patients avoid nerve damage from chemo
Knowledge-focused TerminatedThis pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…
Matched conditions: STAGE IVA OVARIAN CANCER AJCC V8
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC